Skip to main content

Regulatory and Washington

  • FDA approves NDA for Teva's topotecan injection

    SILVER SPRINGS, Md. — Teva Pharmaceuticals has received approval of their new drug application for topotecan hydrochloride injection, a treatment for small cell lung cancer, according to Food and Drug Administration records.

  • Survey: DXM abuse among high school students holds steady at just under 5%

    BETHESDA, Md. — The National Institute on Drug Abuse last week released the 2012 Monitoring the Future survey, finding that 5.6% of high school seniors abused over-the-counter cough and cold medicines containing dextromethorphan, a rate that has held relatively steady over the past five years. Abuse of DXM products was reported to be 3% among eighth graders and 4.7% among tenth graders, bringing the overall average to under 5%.

  • Aegerion receives FDA approval for cholesterol drug, with strongest warning

    CAMBRIDGE, Mass. — The Food and Drug Administration on Monday approved Aegerion Pharmaceuticals' cholesterol drug, Juxtapid.

    The drug — an alternative treatment for patients who have a genetic predisposition to high cholesterol — will carry a boxed warning, the strongest level of FDA warning. Juxtapid will be available only through a restricted program due to risk of liver damage.

  • Ohio becomes 25th state to adopt NPLEx

    WASHINGTON — The Consumer Healthcare Products Association last week applauded Ohio Gov. John Kasich for signing into law House Bill 334, an anti-methamphetamine bill authored by Reps. Terry Johnson, R-Portsmouth, and Danny Bupb, R-West Union. With the new law, Ohio now becomes the 25th state to adopt real-time, stop-sale technology known as the National Precursor Log Exchange.

  • Federal court rules against Endo in painkiller case

    CHADDS FORD, Pa. — A federal court decision means that a nontamper-resistant formulation of a painkiller made by Endo Health Solutions can enter the market early next month, the drug maker said.

    The U.S. District Court for the District of Columbia dismissed a case filed by Endo subsidiary Endo Pharmaceuticals against the Food and Drug Administration, in which the company had argued that the FDA failed meet a legal obligation to determine whether the original formulation of Opana ER (oxymorphone) extended-release tablets was withdrawn from the market for safety reasons.

  • FDA approves biotech drug for reducing symptoms of severe chickenpox infection

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for reducing the severity of chickenpox symptoms, the agency said Friday.

    The FDA announced the approval of Cangene Corp.'s Varizig (varicella zoster immune globulin [human]) for varicella zoster, the virus that causes chickenpox. The FDA said Varizig was the only FDA-approved immune globulin for the virus after exposure.

  • FDA approves Tamiflu in children younger than 1 year

    SILVER SPRING, Md. — The Food and Drug Administration has approved a common flu drug for use in children as young as 2 weeks old, the agency said Friday.

    The FDA announced the new approval for Genentech's Tamiflu (oseltamivir). The agency said that while patients ages 1 year and older can receive the same dosage, those younger than 1 year must be dosed based on their exact weight.

  • FDA approves new drug for short bowel syndrome

    SILVER SPRING, Md. — The Food and Drug Administration has approved a drug to treat a condition that affects people who have had their intestines partially or completely removed, the agency said Friday.

    The FDA announced the approval of NPS Pharmaceuticals' Gattex (teduglutide) for daily injection in adults with short bowel syndrome who need additional nutrition from intravenous feeding. SBS results from partial or complete surgical removal of the small or large intestine, which can lead to poor absorption of fluids and nutrients from food.

X
This ad will auto-close in 10 seconds